Abstract
Purpose
To evaluate biochemical recurrence (BCR) risk in men with localized prostate cancer (PC) of pathological Gleason score (pGS) 8–10. Although such patients have low BCR-free survival (BCRFS) following radical prostatectomy (RP), they are not recommended for adjuvant radiation therapy (ART) as per current guidelines.
Methods
Among an adjuvant treatment-naïve cohort between 1995 and 2015, 1272 men were identified and categorized into group 1 [pGS7 (3 + 4) and pT3; n = 654], group 2 [pGS7 (4 + 3) and pT3; n = 408], and group 3 (pGS 8–10 and pT2; n = 210). The BCR risk of group 3 was compared with that of groups 1 and 2 who are the candidates for ART.
Results
At a median follow-up of 60 months (interquartile range: 39–86), 432 men experienced BCR. BCRFS was lower in group 3 than in groups 1 and 2 (p < 0.001 and p = 0.021, respectively). In multivariate analysis, this association persisted and surgical margin (SM) was found to be a significant BCR predictor. Although statistically not significant, BCRFS was lower in group 3 with positive SM (PSM) than in group 2 with PSM (p = 0.101). BCRFS was significantly worse in group 3 with negative SM (NSM) than in group 1 with PSM (p = 0.038), while it was better in group 2 with PSM (p = 0.297).
Conclusion
Localized high-grade PC with PSM showed lower BCRFS and that with NSM showed better BCRFS without statistical significance than locally advanced GS 7 PC with PSM that are eligible for ART.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Joint Committee on C, Amin MB (2017) AJCC cancer staging manual. Springer, New York
Bolla M et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027. https://doi.org/10.1016/s0140-6736(12)61253-7
Chang SS, Cookson MS (2006) Impact of positive surgical margins after radical prostatectomy. Urology 68:249–252. https://doi.org/10.1016/j.urology.2006.03.053
Cookson MS et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540–545. https://doi.org/10.1016/j.juro.2006.10.097
Cooperberg MR, Hilton JF, Carroll PR (2011) The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117:5039–5046
Cornford P et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002
D’Amico AV et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
de la Taille A, Flam TA, Thiounn N, Pontvert D, Saighi D, Zerbib M, Debre B (2002) Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int 90:887–892
Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA (2013) Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol 190:1735–1741. https://doi.org/10.1016/j.juro.2013.05.053
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading C (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244–252
Fischer S et al (2016) Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int 118:250–257. https://doi.org/10.1111/bju.13319
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523. https://doi.org/10.1097/01.ju.0000045749.90353.c7
Jang WS, Kim LH, Yoon CY, Rha KH, Choi YD, Hong SJ, Ham WS (2016) Effect of preoperative risk group stratification on oncologic outcomes of patients with adverse pathologic findings at radical prostatectomy. PLoS One 11:e0164497. https://doi.org/10.1371/journal.pone.0164497
Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ (2003) Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170:1860–1863. https://doi.org/10.1097/01.ju.0000092503.45951.c2
Kim SP et al (2013) Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology 82:807–812. https://doi.org/10.1016/j.urology.2013.04.060
Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 167:117–122
Menon M et al (2010) Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 58:838–846. https://doi.org/10.1016/j.eururo.2010.09.010
Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, Babaian RJ (2002) Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 167:1675–1680
Mohler JL et al (2016) Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw 14:19–30
Pisansky TM, Thompson IM, Valicenti RK, D’Amico AV, Selvarajah S (2019) Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018–2019. J Urol 202:533–538. https://doi.org/10.1097/ju.0000000000000295
Pound CR, Partin AW, Epstein JI, Walsh PC (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24:395–406
Showalter TN et al (2012) Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys 82:e233–238. https://doi.org/10.1016/j.ijrobp.2011.04.003
Suardi N et al (2012) Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years. Urology 79:133–138. https://doi.org/10.1016/j.urology.2011.08.045
Swanson GP, Riggs M, Hermans M (2007) Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 25:110–114. https://doi.org/10.1016/j.urolonc.2006.06.003
Thompson IM et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239–2246. https://doi.org/10.1056/nejmoa031918
Thompson IM et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190:441–449. https://doi.org/10.1016/j.juro.2013.05.032
Van der Kwast TH et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178–4186. https://doi.org/10.1200/jco.2006.10.4067
Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L (2000) Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 38:372–379. https://doi.org/10.1159/000020311
Funding
This study was supported by a faculty research grant from the Yonsei University College of Medicine (6-2016-0067).
Author information
Authors and Affiliations
Contributions
Conceptualization: JEH, WSH. Methodology: JEH, JSP, JSL, WSH. Formal analysis and investigation: JEH, JK, WSJ, NHC. Writing-original draft preparation: JEH. Writing-review and editing: WSH. Funding acquisition: WSH. Resources: KHR, YDC, SJH. Supervision: WSH.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Institutional review board approval was obtained by the participating center and institutional data sharing agreements were adhered to in accordance with the ethical standards of the institutional and/or national research committee.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Heo, J.E., Park, J.S., Lee, J.S. et al. Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-naïve patients. J Cancer Res Clin Oncol 146, 221–227 (2020). https://doi.org/10.1007/s00432-019-03049-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-03049-0